Table 2 Primary and secondary outcomes for control and ginger-supplemented intervention group
From: Ginger supplement significantly reduced length of hospital stay in individuals with COVID-19
Outcomes | Model estimated | Mean (95% CI) | Intervention difference estimate (95% CI) | P value |
|---|---|---|---|---|
Control | Ginger | |||
Primary outcome | ||||
Participants, no (%) | 132 (58) | 95 (42) | ||
Unadjusted means, d | 8.5 (8.0–9.0) | 6.1 (5.5–6.7) | 2.4 (1.6–3.2) | < 0.0001 |
Adjusted means, d | 8.5 (7.9–9.0) | 6.0 (5.4–6.7) | 2.4 (1.6–3.2) | < 0.0001 |
By sex1 | ||||
Men (n = 147) | ||||
Length of stay, d | 8.9 (8.2–9.5) | 5.8 (5.0–6.6) | 3.0 (2.1–4.0) | < 0.0001 |
Women (n = 80) | ||||
Length of stay, d | 7.8 (6.9–8.8) | 6.7 (5.5–7.8) | 1.2 (-0.26–2.6) | 0.11 |
By Age2 | ||||
Age < 60 (n = 143) | ||||
Length of stay, d | 7.8 (7.1–8.5) | 6.6 (5.9–7.4) | 1.2 (0.28–2.1) | 0.010 |
Age ≥ 60 (n = 84) | ||||
Length of stay, d | 9.9 (9.0–10.7) | 4.9 (3.8–6.1) | 4.9 (3.5–6.4) | < 0.0001 |
By prior medical conditions3 | ||||
W/prior medical conditions (n = 87) | ||||
Length of stay, d | 9.6 (8.9–10.4) | 5.8 (4.7–6.9) | 3.8 (2.5–5.2) | < 0.0001 |
W/O prior medical conditions (n = 140) | ||||
Length of stay, d | 7.9 (7.1–8.6) | 6.1 (5.3–6.8) | 1.8 (0.80–2.8) | 0.0005 |